YES1, the most significantly upregulated gene among IO-exposed tumor cells in this cohort, may explain one specific mechanism via YAP1 (YES-associated protein), which is also associated with poor survival in treatment of treatment naïve ccRCC patients [28, 29]. The gene discussed is YAP1; the disease is nonpapillary renal cell carcinoma.